Skip to main content
Premium Trial:

Request an Annual Quote

RXi Inks Deal to Sell Anti-scarring Drug in EU Prior to Approval

Premium

RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor.

According to RXi, Ethicor will be able to supply the drug before it receives regulatory clearance under EU legislation that allows authorized health care professionals to administer such agents to individual special-needs patients under their care. The unapproved drug may not be marketed to doctors, however.

Under the terms of their deal, RXi and Ethicor will share the sales from RXI-109. Once the drug receives regulatory approval, RXi will regain the marketing rights to the drug.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.